179 related articles for article (PubMed ID: 18793955)
21. BMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiation.
Loriot Y; Mordant P; Dorvault N; De la motte Rouge T; Bourhis J; Soria JC; Deutsch E
Br J Cancer; 2010 Jul; 103(3):347-53. PubMed ID: 20628392
[TBL] [Abstract][Full Text] [Related]
22. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers.
Herbst RS; Langer CJ
Semin Oncol; 2002 Feb; 29(1 Suppl 4):27-36. PubMed ID: 11894011
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit.
Raju U; Molkentine DP; Valdecanas DR; Deorukhkar A; Mason KA; Buchholz TA; Meyn RE; Ang KK; Skinner H
Cancer Med; 2015 Jan; 4(1):65-74. PubMed ID: 25355701
[TBL] [Abstract][Full Text] [Related]
24. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685
[TBL] [Abstract][Full Text] [Related]
25. Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways.
Raju U; Riesterer O; Wang ZQ; Molkentine DP; Molkentine JM; Johnson FM; Glisson B; Milas L; Ang KK
Radiother Oncol; 2012 Nov; 105(2):241-9. PubMed ID: 23010482
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of JAK2 signaling by TG101209 enhances radiotherapy in lung cancer models.
Sun Y; Moretti L; Giacalone NJ; Schleicher S; Speirs CK; Carbone DP; Lu B
J Thorac Oncol; 2011 Apr; 6(4):699-706. PubMed ID: 21325979
[TBL] [Abstract][Full Text] [Related]
27. Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model.
Raben D; Bianco C; Damiano V; Bianco R; Melisi D; Mignogna C; D'Armiento FP; Cionini L; Bianco AR; Tortora G; Ciardiello F; Bunn P
Mol Cancer Ther; 2004 Aug; 3(8):977-83. PubMed ID: 15299080
[TBL] [Abstract][Full Text] [Related]
28. In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase.
Chung EJ; Brown AP; Asano H; Mandler M; Burgan WE; Carter D; Camphausen K; Citrin D
Clin Cancer Res; 2009 May; 15(9):3050-7. PubMed ID: 19366835
[TBL] [Abstract][Full Text] [Related]
29. Anti‑EGFR monoclonal antibody 134‑mG2a exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma.
Hosono H; Takei J; Ohishi T; Sano M; Asano T; Sayama Y; Nakamura T; Yanaka M; Kawada M; Harada H; Kaneko MK; Kato Y
Int J Mol Med; 2020 Oct; 46(4):1443-1452. PubMed ID: 32945346
[TBL] [Abstract][Full Text] [Related]
30. γ-Secretase inhibitor enhances antitumour effect of radiation in Notch-expressing lung cancer.
Mizugaki H; Sakakibara-Konishi J; Ikezawa Y; Kikuchi J; Kikuchi E; Oizumi S; Dang TP; Nishimura M
Br J Cancer; 2012 Jun; 106(12):1953-9. PubMed ID: 22596234
[TBL] [Abstract][Full Text] [Related]
31. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
32. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance.
Zheng Q; Dong H; Mo J; Zhang Y; Huang J; Ouyang S; Shi S; Zhu K; Qu X; Hu W; Liu P; Wang Y; Zhang X
Theranostics; 2021; 11(2):824-840. PubMed ID: 33391507
[TBL] [Abstract][Full Text] [Related]
33. Human epidermal growth factor receptor 3 (HER3) blockade with U3-1287/AMG888 enhances the efficacy of radiation therapy in lung and head and neck carcinoma.
Li C; Brand TM; Iida M; Huang S; Armstrong EA; van der Kogel A; Wheeler DL
Discov Med; 2013 Sep; 16(87):79-92. PubMed ID: 23998444
[TBL] [Abstract][Full Text] [Related]
34. Oridonin Enhances Radiation-Induced Cell Death by Promoting DNA Damage in Non-Small Cell Lung Cancer Cells.
Park H; Jeong YJ; Han NK; Kim JS; Lee HJ
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30104472
[TBL] [Abstract][Full Text] [Related]
35. Anti-alphav integrin monoclonal antibody intetumumab enhances the efficacy of radiation therapy and reduces metastasis of human cancer xenografts in nude rats.
Ning S; Tian J; Marshall DJ; Knox SJ
Cancer Res; 2010 Oct; 70(19):7591-9. PubMed ID: 20841470
[TBL] [Abstract][Full Text] [Related]
36. Histone deacetylase inhibitor NVP-LAQ824 sensitizes human nonsmall cell lung cancer to the cytotoxic effects of ionizing radiation.
Cuneo KC; Fu A; Osusky K; Huamani J; Hallahan DE; Geng L
Anticancer Drugs; 2007 Aug; 18(7):793-800. PubMed ID: 17581301
[TBL] [Abstract][Full Text] [Related]
37. Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models.
Francis DM; Huang S; Armstrong EA; Werner LR; Hullett C; Li C; Morris ZS; Swick AD; Kragh M; Lantto J; Kimple RJ; Harari PM
Clin Cancer Res; 2016 Feb; 22(3):633-43. PubMed ID: 26420857
[TBL] [Abstract][Full Text] [Related]
38. Influence of epidermal growth factor receptor expression on the cetuximab and panitumumab response rates of head and neck carcinoma cells.
Hartmann S; Seher A; Brands RC; Linz C; Lessner G; Böhm H; Kübler AC; Müller-Richter UD
J Craniomaxillofac Surg; 2014 Oct; 42(7):1322-8. PubMed ID: 24780353
[TBL] [Abstract][Full Text] [Related]
39. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.
Benavente S; Huang S; Armstrong EA; Chi A; Hsu KT; Wheeler DL; Harari PM
Clin Cancer Res; 2009 Mar; 15(5):1585-92. PubMed ID: 19190133
[TBL] [Abstract][Full Text] [Related]
40. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer.
Raben D; Helfrich BA; Chan D; Johnson G; Bunn PA
Semin Oncol; 2002 Feb; 29(1 Suppl 4):37-46. PubMed ID: 11894012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]